Acellular Tissue Engineered Vessel (ATEV/HAV)
Arteriovenous (AV) Access for Hemodialysis
Key Facts
About Humacyte
Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.
View full company profileAbout Humacyte
Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.
View full company profileAbout Humacyte
Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.
View full company profileAbout Humacyte
Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.
View full company profile